e-learning
resources
Barcelona 2010
Tuesday, 21.09.2010
Treatment of lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Combination therapy of gefitinib and CYP3A4 inhibitor on non-small-cell lung cancer patients with an
EGFR
mutation and carcinomatous meningitis
S. Okinaga, T. Suzuki, T. Tanaka, H. Miyazawa, K. Hagiwara (Moroyama, Japan)
Source:
Annual Congress 2010 - Treatment of lung cancer
Session:
Treatment of lung cancer
Session type:
Thematic Poster Session
Number:
5047
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Okinaga, T. Suzuki, T. Tanaka, H. Miyazawa, K. Hagiwara (Moroyama, Japan). Combination therapy of gefitinib and CYP3A4 inhibitor on non-small-cell lung cancer patients with an
EGFR
mutation and carcinomatous meningitis. Eur Respir J 2010; 36: Suppl. 54, 5047
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Erlotinib as salvage treatment after failure to gefitinib in non-small cell lung cancer
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009
Cost-effectiveness of afatinib versus erlotinib for the treatment of squamous non-small cell lung cancer in france after a first-line platinum based therapy
Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Year: 2017
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
Source: Eur Respir J 2011; 39: 172-179
Year: 2012
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
Source: Eur Respir J 2012; 39: 172-179
Year: 2012
Treatment of patients with advanced non-small-cell lung cancer (NSCLC) with erlotinib: results from clinical practice
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008
Cost-effectiveness analysis of afatinib vs gefitinib in EGFR-Mutated population with advanced non-small-cell lung cancer
Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Year: 2017
Prevalence and effectiveness of third-line therapy for advanced non-small cell lung cancer (A-NSCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Better quality-of-life in patients with exon 19 deletion receiving first-line tyrosine kinase inhibitors for advanced non-small-cell lung cancer
Source: International Congress 2017 – Noteworthy lung cancer patient reports: reported outcome measures, smoking cessation, weight and sleep disorders
Year: 2017
Combination of erlotinib and bevacizumab in non small cell lung cancer patients
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Possibility of the specific efficacy of gefitinib for miliary lung metastasis in non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 303s
Year: 2004
Second-line therapy in elderly patients with advanced nonsmall cell lung cancer
Source: Eur Respir J 2014; 43: 240-249
Year: 2004
Biphosphonate, ibantronate improves analgesic therapy in non-small lung cancer (NSCLC) patients with bone metastases
Source: Eur Respir J 2005; 26: Suppl. 49, 326s
Year: 2005
Efficacy and safety of Pemetrexed (PEM) for elderly patients with advanced non-small cell lung cancer (NSCLC) who had previous chemotherapy
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
The safety and efficacy of treatment with nab-paclitaxel and carboplatin for patients with advanced squamous non-small cell lung cancer with interstitial lung disease.
Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies
Year: 2017
Phase I trial of lipoplatinÔ and gemcitabine as second line chemotherapy in patients with refractory or resistant advanced non-small-cell lung carcinoma (NSCLC)
Source: Eur Respir J 2007; 30: Suppl. 51, 241s
Year: 2007
Efficacy and prognostic factors of first-line afatinib treatment for the EGFR-mutated non-small cell lung cancer in the real world
Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Year: 2020
Docetaxel in combination with cisplatin in patients with advanced non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 302s
Year: 2004
Chemotherapy in advanced nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 271–283
Year: 2009
Our experience with crizotinib in the treatment of non-small cell lung cancer
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020
The selective EGFR tyrosine-kinase inhibitor erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) – a single institution experience of TRUST – a worldwide open label non randomized phase IV trial
Source: Annual Congress 2007 - Therapy of lung cancer
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept